Catalyst Pharmaceuticals Stock Market Value
| CPRX Stock | USD 21.19 0.29 1.35% |
| Symbol | Catalyst |
Catalyst Pharmaceuticals Price To Book Ratio
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Catalyst Pharmaceuticals. If investors know Catalyst will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Catalyst Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 1.18 | Revenue Per Share 3.999 | Quarterly Revenue Growth 0.253 | Return On Assets 0.1835 | Return On Equity 0.2829 |
The market value of Catalyst Pharmaceuticals is measured differently than its book value, which is the value of Catalyst that is recorded on the company's balance sheet. Investors also form their own opinion of Catalyst Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Catalyst Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Catalyst Pharmaceuticals' market value can be influenced by many factors that don't directly affect Catalyst Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Catalyst Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Catalyst Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Catalyst Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Catalyst Pharmaceuticals 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Catalyst Pharmaceuticals' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Catalyst Pharmaceuticals.
| 10/27/2024 |
| 11/26/2024 |
If you would invest 0.00 in Catalyst Pharmaceuticals on October 27, 2024 and sell it all today you would earn a total of 0.00 from holding Catalyst Pharmaceuticals or generate 0.0% return on investment in Catalyst Pharmaceuticals over 30 days. Catalyst Pharmaceuticals is related to or competes with Eliem Therapeutics, HCW Biologics, Scpharmaceuticals, Milestone Pharmaceuticals, Seres Therapeutics, and Lumos Pharma. Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing ... More
Catalyst Pharmaceuticals Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Catalyst Pharmaceuticals' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Catalyst Pharmaceuticals upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 1.83 | |||
| Information Ratio | (0.03) | |||
| Maximum Drawdown | 9.53 | |||
| Value At Risk | (2.52) | |||
| Potential Upside | 2.92 |
Catalyst Pharmaceuticals Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Catalyst Pharmaceuticals' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Catalyst Pharmaceuticals' standard deviation. In reality, there are many statistical measures that can use Catalyst Pharmaceuticals historical prices to predict the future Catalyst Pharmaceuticals' volatility.| Risk Adjusted Performance | 0.0348 | |||
| Jensen Alpha | (0.06) | |||
| Total Risk Alpha | (0.23) | |||
| Sortino Ratio | (0.03) | |||
| Treynor Ratio | 0.0607 |
Catalyst Pharmaceuticals Backtested Returns
At this stage we consider Catalyst Stock to be very steady. Catalyst Pharmaceuticals secures Sharpe Ratio (or Efficiency) of 0.042, which signifies that the company had a 0.042% return per unit of risk over the last 3 months. We have found twenty-nine technical indicators for Catalyst Pharmaceuticals, which you can use to evaluate the volatility of the firm. Please confirm Catalyst Pharmaceuticals' Mean Deviation of 1.45, downside deviation of 1.83, and Risk Adjusted Performance of 0.0348 to double-check if the risk estimate we provide is consistent with the expected return of 0.0796%. Catalyst Pharmaceuticals has a performance score of 3 on a scale of 0 to 100. The firm shows a Beta (market volatility) of 0.99, which signifies possible diversification benefits within a given portfolio. Catalyst Pharmaceuticals returns are very sensitive to returns on the market. As the market goes up or down, Catalyst Pharmaceuticals is expected to follow. Catalyst Pharmaceuticals right now shows a risk of 1.9%. Please confirm Catalyst Pharmaceuticals potential upside, as well as the relationship between the accumulation distribution and period momentum indicator , to decide if Catalyst Pharmaceuticals will be following its price patterns.
Auto-correlation | -0.38 |
Poor reverse predictability
Catalyst Pharmaceuticals has poor reverse predictability. Overlapping area represents the amount of predictability between Catalyst Pharmaceuticals time series from 27th of October 2024 to 11th of November 2024 and 11th of November 2024 to 26th of November 2024. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Catalyst Pharmaceuticals price movement. The serial correlation of -0.38 indicates that just about 38.0% of current Catalyst Pharmaceuticals price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.38 | |
| Spearman Rank Test | -0.8 | |
| Residual Average | 0.0 | |
| Price Variance | 0.83 |
Catalyst Pharmaceuticals lagged returns against current returns
Autocorrelation, which is Catalyst Pharmaceuticals stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Catalyst Pharmaceuticals' stock expected returns. We can calculate the autocorrelation of Catalyst Pharmaceuticals returns to help us make a trade decision. For example, suppose you find that Catalyst Pharmaceuticals has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Catalyst Pharmaceuticals regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Catalyst Pharmaceuticals stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Catalyst Pharmaceuticals stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Catalyst Pharmaceuticals stock over time.
Current vs Lagged Prices |
| Timeline |
Catalyst Pharmaceuticals Lagged Returns
When evaluating Catalyst Pharmaceuticals' market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Catalyst Pharmaceuticals stock have on its future price. Catalyst Pharmaceuticals autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Catalyst Pharmaceuticals autocorrelation shows the relationship between Catalyst Pharmaceuticals stock current value and its past values and can show if there is a momentum factor associated with investing in Catalyst Pharmaceuticals.
Regressed Prices |
| Timeline |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Catalyst Stock Analysis
When running Catalyst Pharmaceuticals' price analysis, check to measure Catalyst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Catalyst Pharmaceuticals is operating at the current time. Most of Catalyst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Catalyst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Catalyst Pharmaceuticals' price. Additionally, you may evaluate how the addition of Catalyst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.